Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Sage has decided to discontinue the development of its Alzheimer's drug candidate, dalzanemdor, after disappointing mid-stage readouts. This is the third setback in neurology for the company in six months. Meanwhile, cell and gene therapy investments have increased after a challenging period. The Alliance for Regenerative Medicine reported that investments reached $10...